摘要
目的 探讨脑血栓形成急性期患者采用降纤酶治疗的临床效果。方法 收集南阳市中心医院2021年1月至2021年12月脑血栓形成急性期患者的临床资料,采用随机数字表法将90例研究对象分为两组,其中45例给予常规治疗的患者收入对照组,其余45例在常规治疗基础上联合降纤酶治疗的患者收入研究组,比较两组治疗效果。结果 两组治疗前神经功能评分和日常生活能力评分比较差异无统计学意义(P>0.05);治疗后,两组神经功能评分低于治疗前,日常生活能力评分高于治疗前,差异有统计学意义(P<0.05);研究组治疗后神经功能评分低于对照组,日常生活能力评分则高于对照组,差异有统计学意义(P<0.05)。两组治疗前生活质量4个维度评分比较,差异无统计学意义(P>0.05);治疗后,两组评分高于治疗前,差异有统计学意义(P<0.05);研究组治疗后评分高于对照组,差异有统计学意义(P<0.05)。研究组治疗有效率(88.89%)高出对照组(71.11%),差异有统计学意义(P<0.05)。两组治疗前凝血酶原时间(PT)、纤维蛋白原(FG)比较,差异无统计学意义(P>0.05);治疗后,两组FG低于治疗前,PT高于治疗前,差异有统计学意义(P<0.05);研究组治疗后FG低于对照组,PT高于对照组,差异有统计学意义(P<0.05)。结论 降纤酶治疗不仅可以有效调节脑血栓形成急性期患者的纤维蛋白原水平,增加凝血酶时间,还有助于改善神经功能,在提高患者日常生活能力和生活质量的同时对患者的预后转归有着积极影响。
Objective To investigate the clinical effect of defibrase therapy in patients with acute cerebral thrombosis.Methods Clinical data of patients with acute cerebral thrombosis in Nanyang Central Hospital from January to December 2021 were collected.90 cases were divided into two groups by the random number table method. Among them, 45 patients who received conventional treatment were assigned to the control group, and the other 45 patients who received defibrase combined with conventional treatment were assigned to the study group. The treatment effects of the two groups were compared. Results There was no significant difference in the scores of pre-treatment nerve function and daily living ability between the two groups(P>0.05). After treatment, the score of neurological function was lower than before, and the score of daily living ability was higher than before, the difference was statistically significant(P<0.05). The neurological function score of the study group was lower than that of the control group, and the daily living ability score was higher than that of the control group, the difference was statistically significant(P<0.05). There was no significant difference in four dimensions of quality of life between the two groups before treatment(P>0.05). After treatment, the score of the two groups was higher than that before treatment, and the difference was statistically significant(P<0.05). The score of the study group after treatment was higher than that of the control group, and the difference was statistically significant(P<0.05). The effective rate of the study group(88.89%) was higher than that of the control group(71.11%), and the difference was statistically significant(P<0.05). There were no significant differences in prothrombin time(PT) and fibrinogen(FG) between the two groups before treatment(P>0.05). After treatment,FG in the two groups was lower than that before treatment, and PT was higher than that before treatment, the differences were statistically significant(P<0.05). After treatment, FG in the study group was lower than that in the control group, and PT was higher than that in the control group, and the differences were statistically significant(P<0.05). Conclusion Defibrinase therapy can not only effectively regulate the fibrinogen level and increase the thrombin time of patients with acute cerebral thrombosis,but also help to improve the neurological function, improve the daily life ability and quality of life of patients, and have a positive impact on the prognosis of patients.
作者
刘瑞
LIU Rui(The Second Ward of Neurology Department,Nanyang Central Hospital,Nanyang Henan 473000,China)
出处
《临床研究》
2023年第2期89-92,共4页
Clinical Research
